SeaStar Medical Holding Corp (ICU)
SeaStar Medical Holding Corp is a commercial-stage medical device company focused on therapies intended to lessen the effects of hyperinflammation on vital organs. The company’s platform centers on the selective cytopheretic device, or SCD, a treatment designed to help regulate overactive immune responses associated with cytokine storm and related inflammatory damage. Its commercial product, QUELIMMUNE, is an SCD-based therapy for pediatric patients with acute kidney injury due to sepsis. SeaStar Medical is also developing NEUTRALIZE-AKI for adult acute kidney injury, which is being evaluated in clinical trials, along with additional programs in areas such as cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. Founded in 2007 and based in Denver, Colorado, the company’s common stock is listed on NASDAQ under the symbol ICU.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ICU
|
$4.11
|
16.5% Upside
|
Fair
|
$10
|
183.3% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
3.7x
|
9.2x
|
15.556 M
|
8.951 M
|
0.8%
|
99.0%
|
-28.2
|
100.5%
|
